At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 107 enrolled
Drug / intervention
Phleum pratense grass pollen allergen extract +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the SQ Grass SLIT-tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis
In Brief
A Phase 3 clinical trial evaluating Phleum pratense grass pollen allergen extract and placebo for Seasonal Allergic Rhinitis. Completed, enrolled 107 participants across 15 sites.
Detailed Summary
To investigate the immunologic effects and safety of 60-day treatment of the Standardized Quality units (SQ) grass Sublingual immunotherapy (SLIT)-tablet in adult subjects with grass pollen-induced allergic rhinoconjunctivitis in a double-blind, placebo-controlled study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartOct 2014
Primary CompletionMar 2015
TodayJul 2026
First PostedSep 19, 2014
Enrollment StartOct 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.8 years ago
Interventions
Phleum pratense grass pollen allergen extractdrug
Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
placebodrug
placebo tablet given once daily over 60 days